Brief: Anixa Biosciences Initiates Dosing In Third Cohort In Its Ovarian Cancer Car-T Clinical Trial
18/11/2024 13:23
Nov 18 (Reuters) - Anixa Biosciences Inc ANIX.O :
* ANIXA BIOSCIENCES INITIATES DOSING IN THIRD COHORT IN ITS
OVARIAN CANCER CAR-T CLINICAL TRIAL
* ANIXA BIOSCIENCES INC - NO DOSE LIMITING TOXICITY OBSERVED
IN
FIRST AND SECOND COHORTS
Source text: ID:nPn5HjtFBa
Further company coverage: ANIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine